Bavarian Nordic

Denmark-based Bavarian Nordic A/S (CPH: BAVA) has revealed that its pipeline respiratory syncytial virus (RSV) vaccine candidate, MVA-BN RSV, did not achieve all primary endpoints in a Phase III trial. Consequently, the company has decided to discontinue its RSV program, including a co-development partnership with China-based Nuance Pharma for Greater…